Earlier this month, Sapura Energy announced that it had entered into a conditional funding agreement with Malaysia Development Holding Sdn Bhd, with the latter committing to invest up to RM1.1bil ...

Sapura Energy Bhd has returned to the black with a net profit of RM189.53 million for the financial year ended Jan 31, 2025 (FY2025) compared to a net loss of RM508.66 million a year ago.

The increase in margin was driven by lower expenses. Be aware that Sapura Industrial Berhad is showing 2 warning signs in our investment analysis that you should know about... Have feedback on ...

KUALA LUMPUR: Sapura Energy Bhd returned to the black with a net profit of RM189.53 million for the financial year ended Jan 31, 2025 (FY2025), compared to a net loss of RM508.66 million a year ago.

By bno - Surabaya Office Malaysia’s Sapura Energy Bhd, a once respected oil and gas giant in Southeast Asia, has been ...

Profit margin: 3.1% (up from 2.5% in FY 2024). The increase in margin was driven by lower expenses. Be aware that Sapura Industrial Berhad is showing 2 warning signs in our investment analysis that ...

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...

Once a flagship of the oil-rich nation’s ambition to build stalwarts in the upstream energy segment, Sapura Energy is teetering on the brink of collapse – buried under more than RM10 billion (S$3 ...

Kathleen Cleeren is Full Professor of Marketing at KU Leuven. Her research focuses on retailing and investigates the impact of important trends in retailing such as shrinkflation, product-harm ...

While the drug has been approved for use in men, doxycycline post-exposure prophylaxis, also called Doxy PEP, has not been approved for use in women because of a lack of clinical research ...